The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Meta-analysis highlights disparities in CML outcomes across healthcare settings
Jorge Cortes, MD, The University of Alabama at Birmingham, Birmingham, AL, discusses findings from a recent meta-analysis evaluating outcomes with imatinib in chronic myeloid leukemia (CML) across diverse healthcare settings. He highlights persistent disparities in outcomes between large academic centers and smaller institutions, emphasizing the need to improve access to monitoring tools, resources, and standardized care to ensure more equitable treatment for patients with CML worldwide. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
